Fingerprint
Dive into the research topics of 'Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically